Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary clinical data showing that the company’s noninvasive nasal swab test – the first ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Veracyte (VCYT) Tops Q3 EPS by 5c, Slight Beat on Revenue; Reaffirms FY19 Revenue OutlookOctober 22, 2019 4:17 PM Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and DiagnosisOctober 22, 2019 7:00 AM